文献速递小儿眼科与斜弱视

新生儿型与婴儿型原发性先天性青光眼的CYP1B1和MYOC变异比较

CYP1B1 and MYOC variants in neonatal-onset versus infantile-onset primary congenital glaucoma.
PubMed 文献 · Br J Ophthalmol · 2021-09-15

这项前瞻性观察研究纳入43例原发性先天性青光眼(PCG)患儿(新生儿型14例,婴儿型29例),比较两组CYP1B1和MYOC基因变异。携带CYP1B1致病变异的患儿病情更重、预后更差,且新生儿型中CYP1B1突变比例更高(42.8% vs 17.2%),可能是新生儿型PCG预后较差的原因之一。

要点

  • 携带CYP1B1致病变异的PCG患儿病情更重、手术需求更多且预后更差。
  • 新生儿型PCG中CYP1B1突变比例为42.8%(6/14),高于婴儿型的17.2%(5/29)。
  • c.1169G>A [p.R390H]变异在新生儿型中5/6例、婴儿型中3/5例携带,经in-silico分析评分为非常可能致病。

核心结论

  • 携带CYP1B1致病变异的PCG患儿预后比不携带者差。
  • 新生儿型PCG中CYP1B1突变比例高于婴儿型PCG,可能是新生儿型PCG预后较差的原因之一。

研究设计与样本

  • 前瞻性观察研究,纳入2017年1月至2019年1月期间就诊的43例PCG患儿(新生儿型14例,婴儿型29例),随访至少1年。
  • 采用Sanger测序筛查CYP1B1和MYOC基因,并使用Polymorphism Phenotyping v.2和Protein Variation Effect Analyser平台进行in-silico分析。
  • 利用Genome Aggregation Database(gnomAD)估算等位基因频率,并将疾病表现和结局与基因变异进行关联分析。

主要发现

  • 14例新生儿型PCG中6例(42.8%)携带CYP1B1突变,29例婴儿型PCG中5例(17.2%)携带CYP1B1突变。
  • 新生儿型组6例携带者中5例、婴儿型组5例携带者中3例携带c.1169G>A [p.R390H]变异,这些患儿需要更多手术且预后更差。
  • 婴儿型组中2例携带c.1294C>G [p.L432V]变异的患者预后良好。
  • 14例新生儿型PCG中5例、29例婴儿型PCG中8例携带MYOC基因c.227G>A [p.R76K]变异,in-silico分析评分为良性,且15例正常对照中2例也携带该变异。

关键数值与推荐

  • CYP1B1突变在新生儿型PCG中占比42.8%(6/14),在婴儿型PCG中占比17.2%(5/29)。
  • c.1169G>A [p.R390H]变异经in-silico分析评分为非常可能致病(very likely pathogenic)。
  • MYOC基因c.227G>A [p.R76K]变异经in-silico分析评分为良性(benign),并在15例正常对照中2例检出。

临床怎么用

  • 对PCG患儿可考虑进行CYP1B1基因检测,尤其新生儿型PCG,以辅助判断预后和手术需求。
  • 携带CYP1B1致病变异(尤其是c.1169G>A [p.R390H])的患儿可能需要更积极的手术干预和更密切的随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare CYP1B1 and MYOC variants in a cohort of neonatal-onset (NO) and infantile-onset (IO) primary congenital glaucoma (PCG). METHODS: This prospective observational study included 43 infants with PCG (14 NO and 29 IO) presenting between January 2017 and January 2019 with a minimum 1-year follow-up. CYP1B1 and MYOC genes were screened using Sanger sequencing with in-silico analysis of the variants using Polymorphism Phenotyping v.2 and Protein Variation Effect Analyser platforms. Allelic frequency was estimated using Genome Aggregation Database (gnomAd). Disease presentation and outcome were correlated to the genetic variants in both groups. RESULTS: Babies with CYP1B1 mutations had more severe disease at presentation and worse outcomes. Six of 14 (42.8%) NO glaucoma and 5 of 29 (17.2%) IO harboured CYP1B1 mutations. Five of six babies in the NO group and three of five in the IO group harboured the variant c.1169G>A, [p.R390H]. They required more surgeries and had a poorer outcome. On in-silico analysis c.1169G>A, [p.R390H] scored very likely pathogenic. Two patients in the IO group who had the c.1294C>G, [p.L432V] variant had a good outcome. Five of 14 NO-PCG and 8 of 29 IO-PCG harboured the variant c.227G>A, [p.R76K] in the MYOC gene, which was scored benign by in-silico analysis, and was also found in 2 of 15 normal controls. CONCLUSIONS: Patients with CYP1B1 pathogenic variants had a poorer outcome than those without. We found more NO PCG babies with CYP1B1 mutations compared with IO PCG. This may be one of the reasons for NO PCG having a poorer prognosis compared with IO PCG.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kaushik S, Luthra-Guptasarma M, Prasher D, et al. CYP1B1 and MYOC variants in neonatal-onset versus infantile-onset primary congenital glaucoma. Br J Ophthalmol. 2021. PMID: 34526297. doi:10.1136/bjophthalmol-2020-318563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。